ObjectiveTo evaluate the relationship between high sensitivity C-reactive protein(hs-CRP) level,myocardial perfusion and cardiovascular events after percutaneous coronary intervention (PCI) for ST-segment elevation acute myocardial infarction(STEMI) patients.Methods120 cases of STEMI patients received hs-CRP detection after PCI.were selected The patients were divided into the normal hs-CRP group and elevated hs-CRP group according to the hs-CRP levels.Following up for six months,the cardiovascular events of two groups were recorded.Results(1)After PCI,the percentage of TIMI myocardial perfusion grade (TMPG) 0 ～ 1 in the elevated hs-CRP group was higher than that in the normal hs-CRP group,and the percentage of TMPG 3 in the elevated hs-CRP group was lower than that in the normal hs-CRP group ( P ＜ 0.05) ; (2) Following up for six months,the incidence of cardiovascular events in the elevated hs-CRP group was significantly higher than that in the normal hs-CRP group ( P ＜0.05 ).ConclusionFor STEMI patients after PCI,the increasing of hs-CRP indicated the poorly of myocardial perfusion;the early monitoring of hs-CRP was helpful to evaluate the prognosis of acute myocardial infarction after PCI.

ObjectiveTo observe the effect of percutaneous coronary intervention(PCI) treatment on unprotected left main coronary artery(ULMCA) lesion.Methods40 patients with ULMCA lesions treated with PCI were followed up for 6 to 20 months,adverse cardiovascular events (MACE) occurrence were observed.ResultsAll patients treated by immediate PCI success rate was 100.0％.There were no serious complications.There were no serious adverse cardiovascular events during hospitalization.Patients were followed up 6 ～ 20 (7 ± 2) months,4 weeks after operation,acute myocardial infarction in 1 case,CAG confirmed circumflex artery open subacute stent thrombosis,re-PCI cure; postoperative mobilization of 28 patients took CAG in 6 ～ 12 months,including the opening circumflex artery stent restenosis in 3 cases,one distal left anterior descending branch of the trunk opening and then stenosis,2 cases of restenosis in patients with angina symptoms,3 patients re-line PCI,no need to CABG patients.No deaths during followup.The overall incidence of cardiovascular adverse events rate was 12.5％ (5/40),restenosis rate was 10.0％ (4/40).ConclusionThe choice of ULMCA lesions after PCI was safe and feasible,with good short and long term prognosis.

Objective: To explore influence of short-term intervention of different doses rosuvastatin on plasma levels of thrombomodulin (TM) and high sensitive C reactive protein (hsCRP) in patients with acute coronary syndrome (ACS). Methods: A total of 32 ACS patients were enrolled, randomly and equally divided into rosuvastatin 10mg group and rosuvastatin 20mg group, and another 16 patients without coronary heart disease were enrolled as normal control group. Enzyme linked immunosorbent assay (ELISA) was used to measure plasma levels of TM and hsCRP in two rosuvastatin groups before and after treatment and in normal control group at admission. Adverse drug reactions and incidence rates of cardiovascular events within one month were observed in two rosuvastatin groups. Results: Plasma levels of TM and hsCRP in two groups of ACS patients were both significantly higher than those of normal control group before treatment, P<0.001 all; compared with before treatment, there were significant decrease in levels of TM [10mg group：(54.09±52.45) μg/dl vs. (15.65±2.30) μg/dl，20mg group：(70.27±62.43) μg/dl vs. (19.86±5.49) μg/dl] and hsCRP [10mg group：(126.35±76.08) ng/ml vs. (54.85±45.30) ng/ml，20mg group：(125.35±60.29) ng/ml vs. (58.14±53.54) ng/ml] in two rosuvastatin groups after treatment 7d, P<0.01 all; But there were no significant differences in influences of two doses on plasma levels of TM and hsCRP in ACS patients, P＞0.05 all. There was no significant difference in incidence rate of adverse drug reactions between two rosuvastatin groups during follow-up (P>0.05); compared with rosuvastatin 10mg group, there was significant decrease in incidence rate of major adverse cardiovascular events（MACE）: Relapse angina pectoris (62.50% vs. 18.75%, P<0.01) in rosuvastatin 20mg group. Conclusions: Early intensive statins medication （rosuvastatin 20mg）can decrease plasma levels of thrombomodulin and high sensitive C reactive protein, and rosuvastatin 20mg/d can effectively decrease incidence rate of cardiovascular events without significant increase incidence rate of adverse drug reactions in ACS patients.